Skip to Main ContentSkip to FooterSkip to Search
Main menu

Overcoming Challenges for Accelerated Development

The pharmaceutical industry has experienced a trend in the number of accelerated approval designations for drugs (e.g. orphan drugs, breakthrough therapies, accelerated approvals, and FDA priority reviews) being developed.

A View From The R&D Front Lines

Incorporation of patient-focused drug design principles is increasingly becoming essential to ensure that a new drug is commercially successful and delivers the best patient outcomes.